Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Lumizyme (4000L) in Pompe Disease
NCT01526785Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Mar 2012
- Primary completion
- Dec 2014
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Percentage of Participants Who Were Clinically Stable or Improved at Week 52. Started Mar 2012; status: terminated.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01526785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01526785.